{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:48:49Z","timestamp":1778809729889,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clml.2019.12.019","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T16:52:24Z","timestamp":1578502344000},"page":"267-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-2593","authenticated-orcid":false,"given":"Anna","family":"Petrova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Chelysheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-0816","authenticated-orcid":false,"given":"Oleg","family":"Shukhov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-8316","authenticated-orcid":false,"given":"Anastasiya","family":"Bykova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Nemchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Gusarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolay","family":"Tsyba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-7531","authenticated-orcid":false,"given":"Hunan","family":"Julhakyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliy","family":"Shuvaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6552-8023","authenticated-orcid":false,"given":"Mikhail","family":"Fominykh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Martynkevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Ionova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.12.019_bib1","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.12.019_bib2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.019_bib3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.29745","article-title":"Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.019_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.12.019_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.019_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.019_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2019.12.019_bib8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.12.019_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Int Med"},{"key":"10.1016\/j.clml.2019.12.019_bib10","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2019.12.019_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.019_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.019_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-018-0532-2","article-title":"When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"19","author":"Laneuville","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clml.2019.12.019_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12185-017-2295-0","article-title":"Treatment-free remission in patients with chronic myeloid leukemia","volume":"108","author":"Rea","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2019.12.019_bib15","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.019_bib16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.clml.2019.05.007","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after tyrosine kinase inhibitor therapy cessation","volume":"19","author":"Kota","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.12.019_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2019.12.019_bib18","first-page":"33","article-title":"Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia","volume":"7","author":"Katagiri","year":"2017","journal-title":"Leuk Res Rep"},{"key":"10.1016\/j.clml.2019.12.019_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.16083","article-title":"Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome","volume":"187","author":"Berger","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.12.019_bib20","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/j.clml.2019.07.233","article-title":"ENESTop 192-weeks results: treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line nilotinib","volume":"19","author":"Mahon","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.12.019_bib21","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2018-99-116563","article-title":"Updated 18-month results from Dasfree: a study evaluating dasatinib discontinuation in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) and deep molecular response (DMR)","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.019_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl proteinetyrosine kinase inhibitor STI571 inhibits in\u00a0vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2019.12.019_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bcmd.2015.06.010","article-title":"Increased values of the circulating PDGF\u03b2 sustains the \u201cwithdrawal syndrome\u201d after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia","volume":"55","author":"Galimberti","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clml.2019.12.019_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjh.16245","article-title":"Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia","volume":"187","author":"Alfayez","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.12.019_bib26","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/HS9.0000000000000157","article-title":"Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop?","volume":"2","author":"Papalexandri","year":"2018","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2019.12.019_bib27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2018-99-112982","article-title":"Imatinib Suspension and Validation (ISAV) study: final results at 79 months","volume":"132","author":"Mori","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.019_bib28","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s10517-019-04575-0","article-title":"Multipotent mesenchymal stromal cells in patients with chronic myeloid leukemia before discontinuation of tyrosine kinase inhibitors","volume":"167","author":"Petinati","year":"2019","journal-title":"Bull Exp Biol Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:52Z","timestamp":1761870832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S2152265020300045"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}